A comparative trial to check the efficacy of vasavaleha and amritprashyavaleha in the management of asthma

A comparative clinical study on vasavaleha and amritprashyavaleha in the management of tamaka shwasa w.s.r to bronchial asthma - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/101618

Enrollment

Registered

2026-01-20

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1)Patients will have signs and symptoms of Tamaka shwasa 2)patients who are allergic to allopathic medication and willing to have an ayurvedic medicine

Exclusion criteria

Exclusion criteria: 1)Age below 30 and above 60 years 2)patients having complication like CCF, EMPHYSEMA , Pneumonia and multiple complicated disease

Design outcomes

Primary

Measure	Time frame
1. Change in severity of breathlessness (Shwasa Tivrata) 2. Change in frequency of asthmatic attacks (Shwasa Vega) 3. Change in severity of cough (Kasa) 4. Change in wheezing/abnormal respiratory sounds (Kanta Gurgurata) 5. Change in chest discomfort (Urah Shoola) 6. Change in respiratory rateTimepoint: Baseline (Day 0) prior to initiation of treatment Day 7 during the course of treatment Day 15 at completion of treatment	—

Measure

Time frame

1. Change in severity of breathlessness (Shwasa Tivrata) 2. Change in frequency of asthmatic attacks (Shwasa Vega) 3. Change in severity of cough (Kasa) 4. Change in wheezing/abnormal respiratory sounds (Kanta Gurgurata) 5. Change in chest discomfort (Urah Shoola) 6. Change in respiratory rateTimepoint: Baseline (Day 0) prior to initiation of treatment Day 7 during the course of treatment Day 15 at completion of treatment

—

Secondary

Measure	Time frame
1. Change in objective parameters, including: Respiratory rate Hematological parameters: Hemoglobin (Hb%), Total Count (TC), Differential Count (DC), Absolute Eosinophil Count (AEC), & ESR 2. Reduction in frequency of acute exacerbations of Tamaka Shwasa during the treatment period. 3. Improvement in overall clinical status of the patient, as assessed by combined subjective & objective parameters. 4. Assessment of safety & tolerability of Vasavaleha & Amritprashyavaleha by monitoring: Any adverse drug reactions Patient-reported intolerance or discomfort during the treatment periodTimepoint: Duration: 15 days Assessment period: From Day 0 to Day 15	—

Measure

Time frame

1. Change in objective parameters, including: Respiratory rate Hematological parameters: Hemoglobin (Hb%), Total Count (TC), Differential Count (DC), Absolute Eosinophil Count (AEC), & ESR 2. Reduction in frequency of acute exacerbations of Tamaka Shwasa during the treatment period. 3. Improvement in overall clinical status of the patient, as assessed by combined subjective & objective parameters. 4. Assessment of safety & tolerability of Vasavaleha & Amritprashyavaleha by monitoring: Any adverse drug reactions Patient-reported intolerance or discomfort during the treatment periodTimepoint: Duration: 15 days Assessment period: From Day 0 to Day 15

—

Countries

India

Contacts

Public ContactDr Pramod Kutakoli

Shri Shivayogeeshwar Rural Ayurvedic Medical College and Hospital

drpammukutakoli@gmail.com9113859118

Outcome results